David Deperthes, Ph.D. – CEO and President
Founder and CEO of Med Discovery, Dr. Deperthes obtained his Ph.D. in Molecular and Cellular Biology from Laval University in Canada. Discoverer of a new prostate cancer marker, the kallikrein hK2, with Prof. Rolland R. Tremblay, he specialized in the development of new molecules for tumor targeting with J.P. Mach at the ISREC in Lausanne. Dr. Deperthes was Director of the Urology Research Unit at the University Hospital of Lausanne for 5 years. He won the NETS’ Prize in 2003 which consists of an intensive business and management training given at Babson College in Boston to a young entrepreneur selected by the NETS’ prize committee. Dr. Deperthes is also involved in different committees and associations such as Venturekick, Bioalps, or the Swiss Biotech Association.

Claude Blum, Dr. iur., M.C.L.
Claude Blum obtained his Dr. iur. at Zürich University Law School, he then received a Master of Comparative Law from Southern Methodist University Law School, Dallas, Tx, he was admitted to the Bar in Zürich in 1984. He is a partner with Blum&Grob Attorneys at Law Zurich/Switzerland.

Adriano Fontana, PhD Prof
Professor Adriano Fontana, is a graduate from the University of Zürich (1976) where he currently is Prof. Ordinarius of Clinical Immunology and Director of the Immunology Clinic of the University Hospital. A specialist of immunology of the central nervous system, he authored more than 220 original scientific publications. Member of various Editorial and Foundation Boards he received several prices for his outstanding scientific work. He also hold 3 international patents.
Photo courtesy of University of Zurich, Heike Grasser

Manfred Heule (CPA)
Manfred Heule is the CEO and owner of a tax- and business-consulting company in Zurich. As a former partner of one of the “big five” audit companies, a former extraordinary member of a cantonal tax appeal commission and a member of the International Fiscal Association (IFA) he has a wide experience in accounting, finances and taxes.

Grazia Maion, PhD, MBA
Grazia Maion holds a PhD degree in Microbiology Immunology (1995) and a Master degree in Microbiology Immunology (Oncology). In 2003, she also obtained an executive MBA from University of Quebec at Montreal (UQAM). Prior joining the Solidarity Fund QFL as Senior Advisor, Investments, Life Sciences group in September 2001, Dr. Maion has worked as a Technology Transfer Agent at UQAM and within the Commercial Operations and the Clinical Research Group at GlaxoWellcome Inc.

Jean De Serres, MD, MSc, MBA, Chairman of Clinical and Scientific Advisory Board
Dr DeSerres holds a MD and M.Sc from University of Montreal and a MBA in bioindustries from UQAM. At the beginning of his carreer, he practiced medicine and was Director of teaching unit at McGill University as well as President of the Quebec College of Family Physicians. He has also acted as Director of Public Health in Hull, QC prior to joining Aventis Behring Canada as Medical Director and then as General Manager. He is now VP Clinical Research and Regulatory Affairs at Draximage (a division of Draxis Specialty Pharmaceuticals Inc).

Anthony Man B. Med.Sci, M.D. FRCP
Dr. Man holds a degree in biochemistry and a medical degree. He spent many years in academic hospital practice (internal medicine and oncology) and has over 40 scientific publications. During 20 years in international pharmaceutical drug development he has successfully brought more than 10 new molecules to the market, mainly in the area of oncology. Dr. Man currently serves as Chief Executive Officer at Basilea Pharmaceutica AG. a Swiss biopharmaceutical company.

Dr. Christian Gygi, MD - Urologist
Co-Founder of Med Discovery, graduate of the University of Geneva, Switzerland, he began his Urology training in Professor H.-J. Leisinger's department at the University Hospital CHUV in Lausanne. After spending two years in the Urology department of Idianapolis University in the U.S.A. where he exclusively engaged in research in the field of prostatic carcinoma, he returned to Switzerland to become staff urologist. Dr C. Gygi is member of the American Urology Association and he is involved in different medical boards.

Professor Patrice Jichlinski, MD - Urologist
Co-founder of Med Discovery, graduate of the University of Geneva, Switzerland (1979), is associate professor of Urology and Head of the Department of Urology at CHUV-University Hospital in Lausanne Switzerland. He has a special interest in oncologic and reconstructive surgery in Urology with a special interest for bladder cancer and photodynamic applications in this field, in collaboration with the Swiss Federal Institute of Technology (Prof H. van den Bergh). In addition, he is currently involved in basic and clinical research programs. He is member of many scientific societies (AUA, EAU, ESUR, ASLMS, SPIE…).

Norbert Lange, PhD, MBA
Norbert Lange, PhD was born in 1965. After finishing his PhD in Physical Chemistry at University of Göttingen, Germany, in 1996 he joined the Swiss Federal Institute of Technology in Lausanne. Since 2002 he holds a faculty position in the Department of Pharmaceutics and Biopharmaceutics at the Section of Pharmaceutical Sciences at the University of Geneva. His principle interests are in vivo fluorescence imaging, photodynamic therapy and drug formulation.

Sylvain Cloutier, Ph.D.
Dr. Cloutier obtained his Ph.D. in Biochemistry (2002) at Lausanne University. From 2000 to 2002, he was Laboratory Head of the Urology Research Unit at the University Hospital CHUV in Lausanne working on the prostate cancer-specific marker human kallikrein 2 (hK2). Then, as a co-founder and Laboratory Head of Med Discovery, he developed Med Discovery's protease inhibitor technology platform, and using this, the recombinant protease inhibitor MDPK67b, targeting hK2 for the treatment of prostate cancer. Since 2005, he works at Anapharm, a Pharmanet company, located in Canada. Anapharm is a CRO (Clinical Research Organization) Specialized in Clinical development. Dr Cloutier was recently promoted as Clinical Director.

Christian Gygi, M.D
Dr. Christian Gygi, co-founder, is a staff member of the Urology Clinic and is one of the founders of the URU. Graduate of the University of Geneva, Switzerland, (1993) he worked for 2 years at Ely Lilly (Indianapolis, USA) where he exclusively engaged in research in the field of prostate carcinoma.

Patrice Jichlinski, M.D
Co-founder, graduate of the University of Geneva, Switzerland (1988), is a associate professor and Head of the Department of Urology at CHUV in Lausanne, Switzerland. He has a special interest in photodynamic applications of bladder cancer in collaboration with the Swiss Federal Institute of Technology : LPAS-Prof H. van den Bergh. In addition, he is currently involved in a clinical research program with Photocure Inc (Netherlands).

Hans-Jürg Leisinger, M.D
Co-founder of Med Discovery, Professor Leisinger is a graduate of the University of Zurich, Switzerland (1972), Chairman and Head of the Urology Department of CHUV in Lausanne, Switzerland. Since 1992, he has been working in the field of oncologic and reconstructive urology and introduced modern surgical methods in the treatment of localized prostate and bladder cancers.

Professor Jair Ribeiro Chagas, Ph.D.
Professor Chagas obtained his Ph.D. in Molecular Biology from the Federal University of São Paulo, Brazil (1991), where he held an Assistant Professor position from 1992. From 1994 to 1996 he also worked as post-doctoral fellow in the University of Tours, France. From 1999 to 2006, as full Professor and Pro-Rector of Research and Graduate Courses in the University of Mogi das Cruzes, São Paulo, Brazil, he was in charge of creating research facilities and graduate courses on Biotechnology and Biomedical Engineering. In 2006 he moved back to the Federal University of São Paulo in its new campus at Santos, a city on the coast of São Paulo State, to participate in the creation of the new Health Sciences facilities, devoted to undergraduate, graduate and research activities.

Professor Morley D. Hollenberg, Ph.D, MD
Department of Pharmacology&Therapeutics
University of Calgary, Canada

Dr. Jean Bauer, MD - Medical Oncologist
Dr. Bauer is vice-head of medical oncology at the CHUV. He graduated from the University of Lausanne in 1978. Subsequently he followed training in internal medicine and medical oncology in Geneva and Lausanne. Dr. Bauer is an active member of various medical oncology associations, such as ASCO, ESMO, EORTC, SAKK. He has a special interest in urogenital and gynecologic cancer, and in new drug development.

Professor George Thalmann, MD – Urologist
Professor and Chairman of the Department of Urology at the Inselspital, Bern. Recipient of many awards and research grants, Professor Thalmann is very involved in urological research, with a special interest in onco-urology, and membership in many urological and oncology associations (such as ESUR, EORTC, EAU, AACR, AUA). He is on the editorial and review boards of numerous journals in the field and is in high demand to chair urology meetings throughout Europe. He received his medical training at the University of Bern, and completed post-doctoral research at the University of Texas.

Centro de Desenvolvimento de Modelos Experimentais para a Medicina e Biologia
Sao Paulo, Brazil

Professor Alain Hovnanian, MD, PhD
Institut Nationale de la Santé et de la Recherche Médicale
Unit 563, Toulouse, France

Professor Eleftherios P. Diamandis, MD, PhD, FRCP(C)
Department of Pathology & Laboratory Medicine
Mount Sinai Hospital, University of Toronto, Canada

Professor George Thalmann, MD
Department of Urology
Insel Hospital, Bern, Switzerland

Professor Patrice Jichlinski, MD
Department of Urology
University Hospital of Lausanne, Switzerland

Patent and Trademark Attorneys
Geneva, Switzerland

Professor Michel Aguet, MD
Prof. Michel Aguet received his MD in Zürich in 1974. He trained as a postdoctoral fellow in France, and then worked at the University of Zürich as group leader at the Institute of Virology and, from 1989, as Associate Professor at the Institute of Molecular Biology, focusing on the molecular biology of interferons. In 1994 he moved to Genentech Inc., South San Francisco, to head the Molecular Biology Department. In 1996 he was appointed Director of the Swiss Institute for Experimental Cancer Research (ISREC). In 2000 he became the director of the National Center of Competence in Research (NCCR) in Molecular Oncology. In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed Full Professor at the School of Life Sciences in 2005. His current research focuses on the role of embryonic signaling pathways in tumorigenesis and tumor progression.

Christoph Kündig, Ph.D. – Chief Scientific Officer
Dr. Kündig obtained his Ph.D. in life sciences at the Swiss Institute of Technology in Zurich, Switzerland. He joined Professor Marc Ouellette's laboratory at Laval University (Québec, Canada) in 1994 as post-doctoral fellow. He worked on drug target discovery and the molecular biology of Leishmaniosis. He then joined Essential Therapeutics Inc. Company in Mountain View, California as Senior Research Scientist. Med Discovery hired Dr. Kündig as R&D Director at the beginning of its R&D activity to head Med Discovery’s drug discovery, early preclinical and CMC operations. In 2010 Dr. Kündig was promoted CSO to manage the transition of its lead projects from preclinical into early clinical development.

InterPharma Express
Official Representative agent in Japan
Yokohama, Japan